What is Dogwood Therapeutics's enterprise value?

Dogwood Therapeutics (DWTX) reported enterprise value of $57.39M in Q1 2026.

How has Dogwood Therapeutics's enterprise value changed year-over-year?

Dogwood Therapeutics's enterprise value decreased by 46.2% year-over-year, from $106.78M to $57.39M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Dogwood Therapeutics DWTX Enterprise value

Enterprise value at other companies

Eli LillyLLY

$859.77B+10.6%

PfizerPFE

$222.4B+9.2%

Vertex PharmaceuticalsVRTX

$109.92B-9.5%

Collegium Pharmaceutical, Inc.COLL

$765.76M-9.8%

BioventusBVS

$867.64M-8.5%

Avanos MedicalAVNS

$724.37M+3.0%

Other financials

Income statement

See full

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Balance sheet

See full

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Cash flow

See full

Operating cash flow-$4.6M+2.0%

Valuation

See full

Market cap$54.14M-57.6%

Returns & leverage

See full

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Where this comes from

Calculated from Dogwood Therapeutics’s reported figures.

$70.5Mmarket cap+$144.9Ktotal debt−$13.2Mcash and equivalents=$57.39M

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dogwood Therapeutics's enterprise value?: Dogwood Therapeutics (DWTX) reported enterprise value of $57.39M in Q1 2026.
How has Dogwood Therapeutics's enterprise value changed year-over-year?: Dogwood Therapeutics's enterprise value decreased by 46.2% year-over-year, from $106.78M to $57.39M.
What does enterprise value mean?: Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.